Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases
Trial ID or NCT#
Status
Purpose
The goal of this study is to determine whether fractionated Stereotactic radiosurgery (SRS) for spine metastases is associated with improved local tumor control compared to single-fraction SRS. Patients will be randomized to treatment with spine SRS using either 22 Gy in 1 fraction or 28 Gy in 2 fractions.
Official Title
A Randomized Phase III TriaL Comparing SingLe- Versus Multi-Fraction Spine STereotActic Radiosurgery for Patients With Spinal Metastases (ALL-STAR)
Eligibility Criteria
- * Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer Age ≥ 18 years* Patients who have cervical, thoracic, or lumbar spine metastasis that need treatment.* Patients will have 1 to 3 separate spinal sites that require treatment.* Each spinal site to be treated on trial will span 1-2 contiguous vertebral levels* ECOG 0-2* Negative serum or urine pregnancy test within 14 days prior to enrollment for women of childbearing potential or who are not postmenopausal* Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control* Ability to understand and the willingness to sign (personally or by a legal authorized representative) the written IRB approved informed consent document
- * Prior or planned radiation off study within or overlapping with study treatment site* Inability to have either an MRI or a CT scan. Patients with pacemaker will be allowed to undergo CT instead of MRI* Pediatric patients (age \<18 years old), pregnant women, and nursing patients will be excluded* Histology's of myeloma or lymphoma* Patients with strength 1-3 (of 5), bladder incontinence, bowel incontinence, and/or bladder retention that is associated with spinal site to be treated* Prior surgery to spinal site intended to be treated with protocol SRS* Excluded those with SINS 13-18
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Jillian Skerchak
650-721-4072
View on ClinicalTrials.gov